The year Indian pharma was reset

At one minute past midnight on 20 March 2026, semaglutide’s Indian patent expired. It set off the most crowded launch in the industry’s history: more than forty brands, a price collapse of over 90%, and a ₹1,900-crore category that grew and then stalled. Within months, the market learned a hard lesson. Retention beats acquisition.

Semaglutide was not the only shock. Three policy changes landed within nine months. Ten-minute medicine delivery scaled up under rules nobody had finished writing. AI moved from innovation-deck slide to working infrastructure. The Indian Pharma Outlook 2026 reads all of this through one lens: what does it mean for the decisions you make next quarter?

The Indian Pharma Outlook 2026 organises the year into five structural shifts

1. The GLP-1 mass market. A patent expiry created a new category, and then a plateau taught everyone why patient retention matters more than the first prescription.

2. The return of growth. The IPM posted six straight months of double-digit expansion, led by chronic therapies and the domestic market. Broad-based growth, however, is not the same as evenly shared growth.

3. The triple policy reset. GST 2.0 cut medicines to 5%, US tariffs put a one-year clock on the export engine, and the DPCO capped scheduled pricing. Every arrow points home.

4. The channel redrawn. Ten-minute pharmacy is operating on eight-year-old unfinished rules. Meanwhile, the uncounted market below the audit waterline is growing faster than the visible one.

5. AI from pilot to practice. Agentic AI is becoming CRM infrastructure. In India the real play is multiplying engagement in a way that is vernacular, archetype-led and UCPMP-clean.

What’s inside:

Indian Pharma Outlook 2026 runs to 18 chapters in six sections

Section A: The Landscape. State of the IPM 2026.

Section B: The GLP-1 Revolution. The Semaglutide Stampede · Marketing in a “Slum of Brands” · The Plateau and the Fault Lines · Industry Pulse · Obesity as a Category.

Section C: The Policy & Regulatory Reset. GST 2.0 · The Tariff Question · Price Control in 2026.

Section D: Channels & Competition. Ten-Minute Pharma · Fragmentation and the Supply Chain · Contract Manufacturing & Vertical Integration.

Section E: The Demand Side. Consumer Behaviour 2026 · The AI Inflection · Data Gaps and Market Intelligence Challenges.

Section F: From Analysis to Action. Strategic Recommendations for Pharma Marketing Leaders and CEOs.

What makes Indian Pharma Outlook 2026 different

It listens to the industry. A primary survey of 224 pharma professionals, carried out as the semaglutide launch unfolded, captures what the people doing the work actually expected and what they saw.

It keeps score. Most outlooks forget last year’s forecasts. This one grades them in public: what it got right, and what it didn’t.

It ends in action. Every section leads to decisions. You’ll find frameworks for brand plans, field-force design, portfolio choices and patient retention, not just charts to admire.

Who this is for

Indian Pharma Outlook 2026 is written for chief executives and business heads, and for marketing and sales leadership. It serves product managers, brand managers and PMT, as well as medical affairs, market access and commercial strategy teams. It is also for the digital and analytics partners who serve them, and for investors building a view of the Indian market.

About the author

Pranav Kumar has spent three decades building the commercial machinery of Indian pharma. He started in territory management at Cipla and went on to lead marketing, CRM and customer experience at Dr. Reddy’s Laboratories. Through Praakamya https://praakamya.com/, the consultancy he founded in 2018, he advises pharmaceutical companies on brand strategy and experience design. His work draws on two proprietary frameworks: the I.N.S.I.G.H.T.S. brand-planning method and an eight-archetype prescriber-profiling model.

He leads learning programmes at the Infection Control Academy of India (IFCAI) and chaired the CXPA Asia Pacific regional council from 2023 to 2025. He has published the Indian Pharma Outlook annually since 2025.

Recommended Read The Semaglutide Playbook.